Banco Santander S.A. Takes $3.55 Million Position in Moderna, Inc. (NASDAQ:MRNA)

Banco Santander S.A. bought a new position in shares of Moderna, Inc. (NASDAQ:MRNA) in the third quarter, HoldingsChannel.com reports. The institutional investor bought 53,115 shares of the company’s stock, valued at approximately $3,550,000.

Several other hedge funds have also recently bought and sold shares of the business. Commerzbank Aktiengesellschaft FI increased its stake in shares of Moderna by 1.7% in the second quarter. Commerzbank Aktiengesellschaft FI now owns 5,550 shares of the company’s stock valued at $660,000 after purchasing an additional 93 shares during the period. CVA Family Office LLC increased its position in Moderna by 21.6% in the 2nd quarter. CVA Family Office LLC now owns 541 shares of the company’s stock valued at $64,000 after acquiring an additional 96 shares during the period. Claro Advisors LLC raised its stake in Moderna by 2.0% during the 2nd quarter. Claro Advisors LLC now owns 5,546 shares of the company’s stock valued at $659,000 after acquiring an additional 108 shares in the last quarter. McAdam LLC grew its stake in shares of Moderna by 1.1% in the second quarter. McAdam LLC now owns 11,075 shares of the company’s stock worth $1,315,000 after purchasing an additional 117 shares in the last quarter. Finally, 180 Wealth Advisors LLC increased its holdings in shares of Moderna by 1.1% during the second quarter. 180 Wealth Advisors LLC now owns 14,868 shares of the company’s stock valued at $1,826,000 after purchasing an additional 160 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Stock Performance

Shares of MRNA opened at $38.40 on Friday. The company has a market capitalization of $14.78 billion, a PE ratio of -6.60 and a beta of 1.69. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. The company’s 50 day moving average price is $56.13 and its 200 day moving average price is $95.05. Moderna, Inc. has a 52 week low of $35.80 and a 52 week high of $170.47.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. The business had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. Moderna’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.39) earnings per share. Research analysts expect that Moderna, Inc. will post -9.44 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on MRNA. The Goldman Sachs Group decreased their target price on shares of Moderna from $178.00 to $139.00 and set a “buy” rating for the company in a research report on Monday, September 16th. UBS Group lowered their price objective on shares of Moderna from $140.00 to $108.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $75.00 price target on shares of Moderna in a research note on Thursday, September 19th. Hsbc Global Res upgraded Moderna from a “hold” rating to a “strong-buy” rating in a report on Monday. Finally, JPMorgan Chase & Co. lowered their target price on Moderna from $70.00 to $59.00 and set an “underweight” rating on the stock in a report on Monday, November 4th. Three investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $84.00.

Insider Activity

In related news, CFO James M. Mock sold 715 shares of the company’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the sale, the chief financial officer now directly owns 9,505 shares in the company, valued at approximately $571,440.60. This represents a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders sold a total of 2,930 shares of company stock worth $217,170 in the last three months. 15.70% of the stock is owned by insiders.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.